GlassScriptPhysician profile
Arthur S Lieberman
NPI 1992782320
$6,257.89
in general payments reported to CMS, 2019-2025
41 companies · $41.38 in 2025
The $41.38 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $902 · 2020: $917 · 2021: $1,310 · 2022: $1,363 · 2023: $1,329 · 2024: $395 · 2025: $41.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,765.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,765.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $954.32 | 2019-2024 | Mounjaro, Trulicity, Jardiance |
| Abbvie INC. | $714.16 | 2021-2025 | |
| Amgen INC. | $559.82 | 2019-2024 | Repatha, Otezla |
| Novo Nordisk INC | $411.84 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $384.08 | 2019-2024 | |
| Glaxosmithkline, LLC. | $282.81 | 2020-2024 | Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $279.04 | 2019-2023 | Jardiance, Tradjenta |
| Novartis Pharmaceuticals Corporation | $248.48 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $214.75 | 2019-2022 | |
| Amarin Pharma, INC. | $212.13 | 2020-2022 | |
| Esperion Therapeutics, INC. | $195.70 | 2020-2023 | Nexletol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $154.47 | 2022-2024 | Caplyta |
| Paratek Pharmaceuticals, INC. | $154.45 | 2022-2024 | Nuzyra |
| Astrazeneca Pharmaceuticals LP | $147.50 | 2019-2024 | Farxiga, Breztri |
| Vanda Pharmaceuticals INC. | $146.95 | 2020-2021 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Lieberman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.